Flowonix Completes $40 Million Financing

Mount Olive, NJ, November 11, 2014 Flowonix Medical Inc., a medical device company focused on providing advanced, implantable drug delivery solutions, today announced that it has obtained debt and equity financing totaling approximately $40 million.

The transaction includes $20 million in equity investment, led by a private equity fund managed by Élevage Capital Management, LLC. The equity investment also included participation from Clarus Ventures and other existing Flowonix investors, as well as new investors including Hercules Technology Growth Capital, Inc. ("Hercules") (NYSE: HTGC). Additionally, the fundraising included $15.0 million in venture term debt financing and an accounts receivable line credit of up to $5 million from Hercules, provided certain conditions aremet. Armentum Partners acted as the placement agent for the debt financing.

"Our partners at Armentum were instrumental in this process, with their work leading directly to the completion of this important financing round. Through their efforts, we received an overwhelming response from the lender community, which resulted in term sheets from several highly respected organizations. We ultimately selected Hercules as our lender of choice as a result of their strong reputation, enthusiasm toward the potential of our Prometra System, and proven commitment to supporting the efforts of emerging medical technology companies such as Flowonix," said Lou Altieri, CFO of Flowonix.

The Company expects to use the proceeds from this financing to further its investment in sales and marketing infrastructure, new product development and to support the commercialramp of its Prometra Programmable Infusion Pump System in the chronic pain market.

"This additional capital will meaningfully advance our commercial initiatives as we continue to develop the resources necessary to support the rapid growth of our Prometra device. Since securing FDA approval two years ago, we have made great progress in positioning the Prometra System in the market said Steve Adler, President and CEO of Flowonix." "With unparalleled accuracy, longevity and safety, we believe that our technology has the potential to become the gold standard in intrathecal drug delivery for chronic pain treatment, and we look forward to expanding Prometra's footprint as we begin to build and mobilize our sales and support teams and execute on our commercial growth strategy. The chronic pain market represents an opportunity of several hundred million dollars, but with thisadditional capital, we plan to undertake a series of initiatives aimed at further expanding the addressable market for our technology by broadening the universe of patients that can benefit from treatment with the Prometra System. We look forward to providing additional details on these efforts, which will include patients suffering from cancer pain as well as those who fail other implantable treatments."

"Chad Norman, Managing Director of Hercules added, "As we increased our familiarity with the Flowonix story, we have become increasingly enthusiastic toward their technology and its potential in the market. We believe that the Prometra Pump System represents a breakthrough in pump-based drug delivery,and is capable of bringing significant benefit to clinicians and patients alike. We are proud to be a capital provider for Flowonix as the Company ramps its commercial initiatives for this unique, value-added technology solution."

About Flowonix:

Flowonix Medical Inc. (www.flowonix.com), with offices in New Jersey and Massachusetts, is dedicated to working with healthcare professionals to help ease suffering associated with chronic pain and allows patients to reclaim their lives through innovation and therapyadvancements. The strategic business goal of Flowonix Medical Inc. is to become the leading implantable drug delivery company in the world.

Founded in 2005, Flowonix Medical Inc. received approval to conduct its first clinical trial in 2007 on the Prometra programmable implantable pump. The company received approval by the FDA to market the Prometra system in 2012. Flowonix Medical Inc. has been granted multiple patents, and is focused on working closely with physicians to rapidly improve the capabilities of implantable drug delivery and management systems.

For more information, please visit http://www.flowonix.com.

Contacts

Sean Stevenson
[email protected]
(973) 426-9229

The Ruth Group
Lee Roth (investors) / Kirsten Thomas (media)
[email protected] / [email protected] (646) 536-7012 / 7014

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.